HMGB1 as a Late Mediator of Lethal Systemic Inflammation

HAICHAO WANG, HUAN YANG, CHRISTOPHER J. CZURA, ANDREW E. SAMA, and KEVIN J. TRACEY

Departments of Emergency Medicine and Surgery, North Shore University Hospital-New York University School of Medicine, Manhasset, New York

	CONTENTS

TOP CONTENTS PROINFLAMMATORY RESPONSE IN... ANTIINFLAMMATORY RESPONSE IN... THERAPEUTIC CONTROL OF SEPSIS WIDENING THE THERAPEUTIC WINDOW... PERSPECTIVES REFERENCES

Introduction

Proinflammatory Response in Sepsis

Antiinflammatory Response in Sepsis

Therapeutic Control of Sepsis

Widening the Therapeutic Window for Sepsis

  Nuclear HMGB1 as a DNA-binding Protein

  Membrane HMGB1 as a Ligand for RAGE Receptor

  Accumulation of Serum HMGB1 during Endotoxemia

  Anti-HMGB1 Antibodies Protect against Lethal Endotoxemia

  Anti-HMGB1 Antibodies Protect against LPS-induced Acute Lung Injury

  HMGB1 as a Macrophage-activating Cytokine

Perspectives

Gram-negative bacterial infection and systemic inflammation are widespread problems in critically ill patients. Administration of endotoxin (lipopolysaccharide, LPS), a product of gram-negative bacteria, to animals provides a model to study the biological cytokine cascade that is central to the pathophysiology of lethal systemic inflammation. Tumor necrosis factor (TNF) mediates the early cytokine response to lethal endotoxemia, and anti-TNF antibodies have been developed for clinical use in rheumatoid arthritis and Crohn's disease. High-mobility group 1 (HMGB1), a protein previously known only as a nuclear transcription factor, is now implicated as a mediator of delayed endotoxin lethality and systemic inflammation. Here we review the studies that led to the discovery of HMGB1 as a late mediator of systemic inflammation.

	PROINFLAMMATORY RESPONSE IN SEPSIS

TOP CONTENTS PROINFLAMMATORY RESPONSE IN... ANTIINFLAMMATORY RESPONSE IN... THERAPEUTIC CONTROL OF SEPSIS WIDENING THE THERAPEUTIC WINDOW... PERSPECTIVES REFERENCES

The balance of pro- and antiinflammatory mediators derived from the innate immune system defines the progression and severity of endotoxemia. If unbalanced, an overproduction of endogenous proinflammatory mediators, including cytokines, platelet-activating factor, oxygen radicals, and nitric oxide, synergistically interact to mediate hypotension, multiple organ failure, and death. Progression from sepsis to septic shock coincides with an increase in circulating levels of proinflammatory cytokines such as TNF, interferon  (IFN-), interleukin 1 (IL-1), and IL-6 (1). Studies of animal models suggest that inhibition of these early mediators suppresses particular facets of the pathological response. For instance, neutralizing antibodies to TNF, the first cytokine elaborated in the septic inflammatory cascade, prevent death in baboons when administered before or concurrent with lethal doses of live Escherichia coli (2). TNF is a necessary and sufficient mediator of septic shock in experimental animal models. First, TNF is produced in animals during septic shock (3, 4). Second, removing TNF from diseased animals, by either pharmacological strategies or genetic disruption, significantly improves survival after endotoxin challenge (2, 5, 6). Last, administration of TNF to normal animals reproduces the pathological sequelae of septic shock (7, 8). The identification of TNF as an essential mediator of gram-negative septic shock focused attention on the development of therapies directed at endogenous toxins. A number of other proinflammatory cytokines have since been implicated in the mediation of endotoxin lethality. For instance, IL-1 (9, 10), leukemia inhibitory factor (LIF) (11, 12), IFN- (13, 14), and migration inhibitory factor (MIF) (15) may each contribute to the pathogenesis of endotoxemia or septic shock. Clearly, the pathogenesis of sepsis is modulated by an interaction between these and perhaps other mediators. Each of these secondary mediators can be induced by TNF, and a detailed discussion of individual cytokine activities is beyond the scope of this review.

	ANTIINFLAMMATORY RESPONSE IN SEPSIS

TOP CONTENTS PROINFLAMMATORY RESPONSE IN... ANTIINFLAMMATORY RESPONSE IN... THERAPEUTIC CONTROL OF SEPSIS WIDENING THE THERAPEUTIC WINDOW... PERSPECTIVES REFERENCES

The early systemic release of TNF during endotoxemia activates lethal downstream pathological responses (7). Endotoxin also activates "antiinflammatory" mechanisms that counterregulate or suppress potentially injurious proinflammatory mediators. In LPS-stimulated monocytes, for example, the local accumulation of prostaglandin E₂ (PGE₂) inhibits the synthesis of proinflammatory cytokines that can restrain an acute cytokine response (18). Another local feedback mechanism is through spermine, a ubiquitous biogenic molecule that accumulates at sites of infection or injury, and posttranscriptionally inhibits the release of multiple proinflammatory cytokines (e.g., TNF, IL-1, macrophage inflammatory protein 1 [MIP-1], and MIP-1) from macrophages and monocytes (19). Antiinflammatory cytokines (e.g., IL-10 and transforming growth factor  [TGF-]) can participate in the downregulation of the inflammatory response. For instance, IL-10 can deactivate macrophages, and TNF levels in trauma patients are higher when IL-10 levels are depressed, a scenario that has been implicated in the onset of septic complications (23). TGF- is a potent inhibitor of monocyte activation (26), and significantly elevated levels of TGF- have been observed in monocytes derived from immunosuppressed trauma patients (27). New evidence suggests that the central nervous system can directly, and rapidly, attenuate the TNF response to endotoxin through efferent vagus nerve signals to tissue-resident macrophages (28). This effect is mediated by acetylcholine, the principal neurotransmitter of the vagus nerve, which signals via nicotinic cholinergic receptors present on macrophages (28). Thus, the complex cytokine milieu in septic patients is characterized by the interaction between antiinflammatory responses and potentially injurious proinflammatory responses that are tightly regulated by neural and humoral pathways.

	THERAPEUTIC CONTROL OF SEPSIS

TOP CONTENTS PROINFLAMMATORY RESPONSE IN... ANTIINFLAMMATORY RESPONSE IN... THERAPEUTIC CONTROL OF SEPSIS WIDENING THE THERAPEUTIC WINDOW... PERSPECTIVES REFERENCES

Several therapeutic agents that target TNF have been tested in clinical trials of sepsis, and a significant survival advantage has not been observed. One confounding factor is that TNF levels are not usually increased in enrolled patients, in part because of the rapid kinetics of the TNF response (29, 30). Serum TNF and IL-1 reach toxic levels in mice and human volunteers within 1-2 h after LPS infusion (3, 31), but delayed treatment with anti-TNF or anti-IL-1 fails to prevent late endotoxin deaths (2, 32). Paradoxically, endotoxin-responsive mice treated with lethal doses of endotoxin often succumb at latencies of up to 5 d, long after serum TNF and IL-1 have returned to basal levels (Figure 1). Transgenic mice rendered devoid of TNF receptors, although partially protected from endotoxin lethality, die several days after high-dose LPS administration (33, 34). On the basis of these and other observations, we reasoned that treatment strategies might be developed to target late-acting, clinically accessible mediators that are distinct from TNF. The combined insights gained from the failure of clinical trials of anti-TNF strategies (35, 36), as well as the observations surrounding the kinetics of TNF release as compared with the onset of lethality (3, 31), prompted a search for a late mediator of endotoxin-induced death.

View larger version (19K): [in this window] [in a new window]   Figure 1.   Early versus late mediators of endotoxin lethality. Vertebrates treated with lethal doses of LPS succumb at latencies of up to several days, long after serum TNF and IL-1 have returned to basal levels. The kinetics of HMGB1 release is delayed, and parallels the onset of lethality.

	WIDENING THE THERAPEUTIC WINDOW FOR SEPSIS

TOP CONTENTS PROINFLAMMATORY RESPONSE IN... ANTIINFLAMMATORY RESPONSE IN... THERAPEUTIC CONTROL OF SEPSIS WIDENING THE THERAPEUTIC WINDOW... PERSPECTIVES REFERENCES

In an effort to broaden the therapeutic window for sepsis, we initiated a search for another macrophage-derived, putative mediator released relatively late after the onset of endotoxemia. We stimulated murine macrophage-like RAW 264.7 cells with LPS and screened the conditioned medium for proteins appearing after 16 h. LPS induced the appearance of a 30-kDa protein in the conditioned medium that was not apparent at earlier time points. The N-terminal amino acid sequence of the 30-kDa protein (i.e., G-K-G-D-P-K-K-P-R-G-K-M-S-S) was identical to murine HMGB1, a member of the high-mobility group 1 nonhistone chromosomal protein family (37, 38).

Nuclear HMGB1 as a DNA-binding Protein

Approximately 30 yr ago, HMGB1 was first copurified from nuclei with histones, and termed "high-mobility group" (HMG) protein because of its rapid mobility on electrophoresis gels (39). As a highly conserved protein, HMGB1 shares 100% identity in amino acid sequence between mouse and rat, and a 99% amino acid identity between rodent and human (37, 38, 40). HMG-1 has been renamed HMGB1 by a nomenclature committee (41). As a nonhistone chromosomal protein, HMGB1 has been implicated in diverse cellular functions, including determination of nucleosomal structure and stability, and binding of transcription factors to their cognate DNA sequences (42). Highly charged HMGB1 contains a continuous stretch of negatively charged (aspartic and glutamic acid) residues in the C terminus, and two internal repeats of positively charged domains ("HMG boxes") in the N terminus (Figure 2) (43). The HMG boxes provide the structure-specific binding sites for DNA with secondary structures such as supercoiled DNA (44), cruciform DNA (45), four-way junctions (46, 47), and cisplatin-damaged DNA (48). These observations suggested a possible role for HMGB1 in DNA recombination, repair, replication, and gene transcription (42). Although HMGB1 has not been associated with gene transcription in vivo (49), it can stimulate transcription in vitro (50). HMGB1 bends DNA and facilitates binding of various transcription factors to their cognate sequences, including the steroid/nuclear hormones progesterone (53) and estrogen (54, 55), HOX proteins (50), and transcription factor II B (56). Hmg1-deficient mice are viable only for a few hours after birth, although parenterally administered glucose can prolong survival for a few days (57). The lack of chromosomal HMGB1 protein does not disrupt cell growth, but may affect the transcriptional regulation of certain genes, such as those activated by the glucocorticoid receptor (57).

View larger version (23K): [in this window] [in a new window]   Figure 2.   Amino acid sequence of murine HMGB1. The C-terminal portion of HMGB1 contains a continuous sequence between 35 and 40 aspartic and glutamic acid residues, and the N-terminal portion of HMGB1 comprises two internal repeats of a positively charged domain of about 80 amino acids (termed "HMG boxes") (shown by underlines).

Membrane HMGB1 as a Ligand for RAGE Receptor

HMGB1 localizes to the nucleus and cytoplasm of most cells, to the cell membrane of neuronal (neuroblastoma) cells (58), and to the filopodia of the advancing plasma membrane of neurites (58, 59), where it colocalizes and interacts with tissue plasminogen activator (t-PA). Membrane HMGB1 has been termed "amphoterin" because it has marked dipolar charge properties (Figure 2) (58). Local acceleration of t-PA-catalyzed plasminogen activation by HMGB1 at the leading edge of the cytoplasmic membrane has been implicated in cell migration (60), differentiation, and regeneration (61). HMGB1 can bind to the receptor for advanced glycation end products (RAGE) in a dose-dependent manner (63). The interaction between HMGB1 and RAGE can be competitively inhibited by addition of soluble RAGE or anti-RAGE IgG (63). RAGE is expressed on mononuclear phagocytes and vascular smooth muscle cells (62, 64, 65), and engagement of RAGE with ligands (such as advanced glycation end products [AGE], or HMGB1), activates not only the NF-B signaling pathway (64, 66), but also the mitogen-activated protein kinase (MAPK) pathways (67).

Accumulation of Serum HMGB1 during Endotoxemia

To study the biology of HMGB1 as a mediator of systemic inflammation, recombinant HMGB1 (rHMGB1) was expressed in E. coli, purified to homogeneity, and used to generate polyclonal anti-HMGB1 antibodies for developing a quantitative immunoassay (68). Large amounts of HMGB1 are released by macrophage cultures in a time-dependent manner, with significant HMGB1 accumulation first detectable after 8 h of LPS stimulation (68). HMGB1 release by LPS-stimulated macrophages was not due to cell death, as judged by trypan blue exclusion and lactate dehydrogenase (LDH) release. The inducible nature of HMGB1 release has been observed in murine primary peritoneal macrophages, human primary peripheral blood mononuclear cells (huPBMCs) (68), as well as murine pituitary cells after stimulation with proinflammatory cytokines (e.g., TNF and IL-1) (69). Notably, TNF- and IL-1-mediated inflammatory effects are often highly synergistic. For instance, TNF and IL-1 have been shown to interact synergistically in inducing polymorphonuclear leukocyte migration (70), and the production of cytokines (e.g., IL-6) (71) and prostaglandin E₂ (PGE₂) (72). It remains to be investigated whether such a synergistic interaction between TNF and IL-1 plays a role in the regulation of HMGB1 release during systemic inflammation.

Systemic HMGB1 accumulation during endotoxemia was measured in the serum of mice after LPS administration. Serum HMGB1 was minimally detectable by 8 h after administration of a median lethal dose (LD₅₀) of LPS, and increased to a prolonged plateau level from 16 to 32 h after LPS treatment. This delayed release distinguishes HMGB1 from previously described early cytokine mediators of LPS lethality. In view of the late and prolonged kinetics of HMGB1 in mice, we thought that it might be possible to detect increased serum HMGB1 levels in critically ill patients, because clinical signs of sepsis typically develop long after the early cytokine response to the acute infection. We probed for immunoreactive material in the serum of 8 healthy normal subjects and 25 critically ill patients with surgical sepsis and sepsis-induced organ dysfunction (i.e., hypotension, lactic acidosis, disseminated intravascular coagulation, hypoxemia, or decreased urine output) secondary to infection. Serum HMGB1 was not detectable in serum of normal subjects, but was significantly increased in all critically ill patients with sepsis (68). Moreover, serum HMGB1 levels were significantly higher in septic patients who did not survive as compared with survivors (68).

Hemorrhagic shock, like septic shock, is characterized by activation of a cytokine cascade, even in the absence of an initial stimulation by bacterial products. As with septic shock, TNF is released during hemorrhagic shock (73), and plays an important role in the pathophysiology of the disease (74). Because TNF can induce the release of HMGB1 from macrophage-monocyte (68) and pituicyte cultures (69), it is possible that hemorrhagic shock itself, in the absence of infection, can stimulate the systemic release of HMGB1. Indeed, in a clinical case, serum HMGB1 levels increased significantly within 24 h after the onset of hemorrhagic shock, and returned toward basal levels as the clinical condition improved (75). The role of other inflammatory stimuli in activating HMGB1 release in the absence of infection is unclear.

Anti-HMGB1 Antibodies Protect against Lethal Endotoxemia

The biological role of extracellular HMGB1 was studied in vivo by passive immunization of unanesthetized endotoxemic mice. A single dose of anti-HMGB1 antiserum administered 30 min before an LD₁₀₀ dose of LPS failed to prevent LPS-induced death. The delayed kinetics of HMGB1 accumulation in serum suggested to us that effective neutralization of a late-appearing mediator might require delayed dosing with antibodies. By treating animals with three doses of antiserum (30 min before LPS, and 12 and 36 h after LPS), we observed a significant improvement in survival, with 70% of treated animals surviving as compared with 0% survival of controls treated with three matched doses of preimmune serum. Delaying the first dose of anti-HMGB1 antibodies for at least 2 h after LPS still conferred significant protection against an LD₁₀₀ dose of LPS (68). More recent data (H. Yang and K. J. Tracey, unpublished) indicate that anti-HMGB1 antibodies confer significant protection against sepsis in an animal model of cecal perforation, even when antibody administration is delayed by 24 h. This suggests that it may now be possible to develop inhibitors of HMGB1 for treatment of systemic inflammation, and that the therapeutic window for these therapies may be significantly wider than for TNF-targeted interventions.

Anti-HMGB1 Antibodies Protect against LPS-induced Acute Lung Injury

Systemic inflammation is frequently complicated by lung injury. In a widely used animal model of LPS-induced acute lung injury, administration of anti-HMGB1 either before or after endotoxin treatment significantly decreased endotoxin-induced neutrophil accumulation into the lungs, and attenuated the severity of lung edema produced by intratracheal administration of endotoxin (76). Despite the ameliorative effects of anti-HMGB1 antibodies on the development of lung injury and neutrophil accumulation, this treatment had no effect on endotoxin-induced increases in pulmonary concentrations of IL-1, TNF, or MIP-2, indicating that endogenous HMGB1 is a mediator of acute lung injury. The role of HMGB1 in the pathogenesis of acute lung injury appears to be distinct from the effect on early-acting proinflammatory cytokines. To examine the toxicity of HMGB1 itself, a highly purified preparation of HMGB1 was administered intratracheally to LPS-resistant C3H/ HeJ mice. Lung neutrophil accumulation and edema increased in a dose-dependent manner at 8 and 24 h after HMGB1 administration. Intratracheal administration of HMGB1 led to significant increases in tissue levels of proinflammatory cytokines, including IL-1, TNF, and MIP-2. Histological examination of tissue sections prepared from the lungs of animals treated for 24 h with pathophysiological doses of HMGB1 revealed evidence of an acute diffuse inflammatory response, with accumulation of neutrophils in the interstitial and intraalveolar areas, interstitial edema, and protein exudation into the alveolar space (76). These pathological changes are typically observed in response to acute lung injury mediated by endotoxin, TNF, and other proinflammatory stimuli. However, these effects could not be attributed to trace amounts of endotoxin coadministered with the HMGB1, because C3H/HeJ mice do not respond to low doses of endotoxin. It is reasonable to consider that HMGB1 may contribute to the pathogenesis of acute lung injury and systemic inflammation.

HMGB1 as a Macrophage-activating Cytokine

The data reviewed above were the first to implicate HMGB1 as a cytokine. To further examine the cytokine activity of HMGB1, HMGB1 was added to human primary blood mononuclear cell cultures. HMGB1 significantly increased the release of TNF in a dose-dependent manner (77). Upregulation of TNF mRNA after treatment with HMGB1 was observed within 4 h after addition of rHMGB1, but peak TNF mRNA levels were not achieved for 10 h. This stimulation was not attributable to small quantities of LPS that may have contaminated the rHMGB1, for several reasons. First, the kinetics for HMGB1- and LPS-induced TNF synthesis are distinctly different, with the late peak for HMGB1-stimulated TNF synthesis (8-10 h after stimulation) being incompatible with the rapid kinetics for LPS-induced TNF synthesis (peaks within 2-3 h). Second, coaddition of LPS-neutralizing agents such as polymyxin B in amounts that exceeded by 100-fold the concentration necessary to neutralize contaminating LPS (as revealed by the Limulus amebocyte lysate [LAL] endotoxin assay) fails to inhibit HMGB1-induced cytokine synthesis. Third, proteolytic degradation of HMGB1 by trypsin abolishes the activity of HMGB1 as a cytokine stimulus, whereas treatment of LPS with trypsin does not affect the activity of LPS in stimulating TNF release (77). Pathological doses of HMGB1 amplify the cytokine cascade during systemic inflammation; however, the contribution of this delayed TNF activity to the pathology of inflammation has yet to be determined. Together, the release of HMGB1 by activated macrophages, its causative role in lethal endotoxemia, and its activity as a macrophage-stimulating agent (Table 1) reveal that HMGB1 is a late cytokine mediator of systemic inflammation.

	PERSPECTIVES

TOP CONTENTS PROINFLAMMATORY RESPONSE IN... ANTIINFLAMMATORY RESPONSE IN... THERAPEUTIC CONTROL OF SEPSIS WIDENING THE THERAPEUTIC WINDOW... PERSPECTIVES REFERENCES

HMGB1 was first identified as a nuclear chromosomal protein that participates in maintenance of nucleosomal structure and stability, and regulation of gene expression by facilitating the binding of transcription factors to their cognate DNA sequences (42). It is now clear that HMGB1 is also a late cytokine mediator of endotoxemia released into the extracellular milieu. The chronology of events in elucidating the biological role of HMGB1 shares an interesting antiparallel relationship with the discovery of IL-1. IL-1 was initially characterized as a cytokine, but subsequently found to function as a transcription factor once transported from the cell membrane to the nucleus (78). It is interesting to consider that extracellular HMGB1 may be transported to the nucleus, where it might interact with transcription factors. The discovery of HMGB1 as a monocyte-derived, late-acting cytokine mediator of endotoxin lethality has initiated a new field of investigation for development of experimental therapeutics. The downstream or "late" action of HMGB1 is a marked departure from the early activities of TNF and other classic proinflammatory cytokines, and has significant implications for understanding and manipulating innate immune responses. Unpublished data (H. Wang and K. J. Tracey) suggest that it may be possible to develop antiinflammatory therapeutics that inhibit HMGB1 release and prevent death in murine sepsis. The insights gained from these and other studies of HMGB1 may widen the therapeutic window for treatment of endotoxemia, septic shock, and sepsis, if this newly recognized cytokine proves to be a clinically accessible target.

	Footnotes

Correspondence and requests for reprints should be addressed to Haichao Wang, Ph.D., Department of Emergency Medicine, North Shore University Hospital-New York University School of Medicine, 350 Community Drive, Manhasset, NY 11030. E-mail: hwang{at}nshs.edu

(Received in original form June 22, 2001 and accepted in revised form September 20, 2001).

	References

TOP CONTENTS PROINFLAMMATORY RESPONSE IN... ANTIINFLAMMATORY RESPONSE IN... THERAPEUTIC CONTROL OF SEPSIS WIDENING THE THERAPEUTIC WINDOW... PERSPECTIVES REFERENCES

1. Ayala A, Chaudry IH. Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Shock 1996;6(Suppl 1):S27-S38.

2. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-664 [Medline].

3. Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA Jr,, Cerami A, Shires GT, Lowry SF. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166: 147-153 [Medline].

4. Marano MA, Fong Y, Moldawer LL, Wei H, Calvano SE, Tracey KJ, Barie PS, Manogue K, Cerami A, Shires GT, et al . . Serum cachectin/ tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet 1990; 170: 32-38 [Medline].

5. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Kronke M, Mak TW. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993; 73: 457-467 [Medline].

6. Emerson TEJ, Lindsey DC, Jesmok GJ, Duerr ML, Fournel MA. Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model. Circ Shock 1992; 38: 75-84 [Medline].

7. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ III,, Zentella A, Albert JD, et al . . Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-474 [Abstract/Free Full Text].

8. Tracey KJ, Lowry SF, Fahey TJ III,, Albert JD, Fong Y, Hesse D, Beutler B, Manogue KR, Calvano S, Wei H, et al . . Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 1987; 164: 415-422 [Medline].

9. Dinarello CA. The role of interleukin-1 in host responses to infectious diseases. Infect Agents Dis 1992; 1: 227-236 [Medline].

10. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12: 404-410 [Medline].

11. Block MI, Berg M, McNamara MJ, Norton JA, Fraker DL, Alexander HR. Passive immunization of mice against D factor blocks lethality and cytokine release during endotoxemia. J Exp Med 1993; 178: 1085-1090 [Abstract/Free Full Text].

12. Waring PM, Waring LJ, Metcalf D. Circulating leukemia inhibitory factor levels correlate with disease severity in meningococcemia. J Infect Dis 1994; 170: 1224-1228 [Medline].

13. Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, Norton JA. Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. J Immunol 1992; 149: 1666-1670 [Abstract].

14. Heinzel FP. The role of IFN-gamma in the pathology of experimental endotoxemia. J Immunol 1990; 145: 2920-2924 [Abstract].

15. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993; 365: 756-759 [Medline].

16. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6: 164-170 [Medline].

17. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999; 189: 341-346 [Abstract/Free Full Text].

18. Knudsen PJ, Dinarello CA, Strom TB. Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol 1986; 137: 3189-3194 [Abstract].

19. Zhang M, Caragine T, Wang H, Cohen PS, Botchkina G, Soda K, Bianchi M, Ulrich P, Cerami A, Sherry B, et al . . Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counterregulatory mechanism that restrains the immune response. J Exp Med 1997; 185: 1759-1768 [Abstract/Free Full Text].

20. Zhang M, Borovikova LV, Wang H, Metz C, Tracey KJ. Spermine inhibition of monocyte activation and inflammation. Mol Med 1999; 5: 595-605 [Medline].

21. Wang H, Zhang M, Bianchi M, Sherry B, Sama A, Tracey KJ. Fetuin (₂-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules. Proc Natl Acad Sci USA 1998; 95: 14429-14434 [Abstract/Free Full Text].

22. Zhang M, Wang H, Tracey KJ. Regulation of macrophage activation and inflammation by spermine: a new chapter in an old story. Crit Care Med 2000; 28: N60-N66 [Medline].

23. Hauser CJ, Lagoo S, Lagoo A, Hale E, Hardy KJ, Barber WH, Bass JD, Poole GV. Tumor necrosis factor  gene expression in human peritoneal macrophages is suppressed by extra-abdominal trauma. Arch Surg 1995; 130: 1186-1191 [Abstract].

24. Oswald IP, Wynn TA, Sher A, James SL. Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor  required as a costimulatory factor for interferon -induced activation. Proc Natl Acad Sci USA 1992; 89: 8676-8680 [Abstract/Free Full Text].

25. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10.  J Exp Med 1991; 174: 1549-1555 [Abstract/Free Full Text].

26. Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-. Nature 1988; 334: 260-262 [Medline].

27. Miller-Graziano CL, Szabo G, Griffey K, Mehta B, Kodys K, Catalano D. Role of elevated monocyte transforming growth factor beta (TGF ) production in posttrauma immunosuppression. J Clin Immunol 1991; 11: 95-102 [Medline].

28. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-462 [Medline].

29. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-, and interferon- in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis 1990; 161: 982-987 [Medline].

30. Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF. Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis 1990; 141: 94-97 [Medline].

31. Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 1985; 135: 3972-3977 [Abstract].

32. Fink MP. Another negative clinical trial of a new agent for the treatment of sepsis: rethinking the process of developing adjuvant treatments for serious infections (editorial; comment). Crit Care Med 1995; 23: 989-991 [Medline].

33. Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, Jungbluth A, Wada H, Moore B, Williamson B, et al . . Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997; 94: 8093-8098 [Abstract/Free Full Text].

34. Amiot F, Fitting C, Tracey KJ, Cavaillon JM, Dautry F. Lipopolysaccharide-induced cytokine cascade and lethality in LT /TNF -deficient mice. Mol Med 1997; 3: 864-875 [Medline].

35. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech 2000; 50: 229-235 [Medline].

36. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, et al . . Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF- MAb Sepsis Study Group. JAMA 1995; 273: 934-941 [Abstract].

37. Ferrari S, Ronfani L, Calogero S, Bianchi ME. The mouse gene coding for high mobility group 1 protein (HMG1). J Biol Chem 1994; 269: 28803-28808 [Abstract/Free Full Text].

38. Paonessa G, Frank R, Cortese R. Nucleotide sequence of rat liver HMG1 cDNA. Nucleic Acids Res 1987; 15: 9077 [Free Full Text].

39. Johns EW. History, definitions and problems. In: Johns EW, editor. The HMG chromosomal proteins. London: Academic Press; 1982. p. 1-8.

40. Wen L, Huang JK, Johnson BH, Reeck GR. A human placental cDNA clone that encodes nonhistone chromosomal protein HMG-1. Nucleic Acids Res 1989; 17: 1197-1214 [Abstract/Free Full Text].

41. Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 2001; 26: 152-153 [Medline].

42. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999; 19: 5237-5246 [Free Full Text].

43. Landsman D, Bustin M. A signature for the HMG-1 box DNA-binding proteins. Bioessays 1993; 15: 539-546 [Medline].

44. Stros M, Reich J. Formation of large nucleoprotein complexes upon binding of the high-mobility-group (HMG) box B-domain of HMG1 protein to supercoiled DNA. Eur J Biochem 1998; 251: 427-434 [Medline].

45. Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science 1989; 243: 1056-1059 [Abstract/Free Full Text].

46. Hill DA, Pedulla ML, Reeves R. Directional binding of HMG-I(Y) on four-way junction DNA and the molecular basis for competitive binding with HMG-1 and histone H1. Nucleic Acids Res 1999; 27: 2135-2144 [Abstract/Free Full Text].

47. Hill DA, Reeves R. Competition between HMG-I(Y), HMG-1 and histone H1 on four-way junction DNA. Nucleic Acids Res 1997; 25: 3523-3531 [Abstract/Free Full Text].

48. Locker D, Decoville M, Maurizot JC, Bianchi ME, Leng M. Interaction between cisplatin-modified DNA and the HMG boxes of HMG 1: DNase I footprinting and circular dichroism. J Mol Biol 1995; 246: 243-247 [Medline].

49. Landsman D, Bustin M. Assessment of the transcriptional activation potential of the HMG chromosomal proteins. Mol Cell Biol 1991; 11: 4483-4489 [Abstract/Free Full Text].

50. Zappavigna V, Falciola L, Helmer-Citterich M, Mavilio F, Bianchi ME. HMG1 interacts with HOX proteins and enhances their DNA binding and transcriptional activation. EMBO J 1996; 15: 4981-4991 [Medline].

51. Ge H, Roeder RG. The high mobility group protein HMG1 can reversibly inhibit class II gene transcription by interaction with the TATA-binding protein. J Biol Chem 1994; 269: 17136-17140 [Abstract/Free Full Text].

52. Aizawa S, Nishino H, Saito K, Kimura K, Shirakawa H, Yoshida M. Stimulation of transcription in cultured cells by high mobility group protein 1: essential role of the acidic carboxyl-terminal region. Biochemistry 1994; 33: 14690-14695 [Medline].

53. Onate SA, Prendergast P, Wagner JP, Nissen M, Reeves R, Pettijohn DE, Edwards DP. The DNA-bending protein HMG-1 enhances progesterone receptor binding to its target DNA sequences. Mol Cell Biol 1994; 14: 3376-3391 [Abstract/Free Full Text].

54. Zhang CC, Krieg S, Shapiro DJ. HMG-1 stimulates estrogen response element binding by estrogen receptor from stably transfected HeLa cells. Mol Endocrinol 1999; 13: 632-643 [Abstract/Free Full Text].

55. Verrier CS, Roodi N, Yee CJ, Bailey LR, Jensen RA, Bustin M, Parl FF. High-mobility group (HMG) protein HMG-1 and TATA-binding protein-associated factor TAF(II)30 affect estrogen receptor-mediated transcriptional activation. Mol Endocrinol 1997; 11: 1009-1019 [Abstract/Free Full Text].

56. Sutrias-Grau M, Bianchi ME, Bernues J. High mobility group protein 1 interacts specifically with the core domain of human TATA box-binding protein and interferes with transcription factor IIB within the pre-initiation complex. J Biol Chem 1999; 274: 1628-1634 [Abstract/Free Full Text].

57. Calogero S, Grassi F, Aguzzi A, Voigtlander T, Ferrier P, Ferrari S, Bianchi ME. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice (see comments). Nat Genet 1999; 22: 276-280 [Medline].

58. Merenmies J, Pihlaskari R, Laitinen J, Wartiovaara J, Rauvala H. 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem 1991; 266: 16722-16729 [Abstract/Free Full Text].

59. Rauvala H, Huttunen HJ, Fages C, Kaksonen M, Kinnunen T, Imai S, Raulo E, Kilpelainen I. Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility. Matrix Biol 2000; 19: 377-387 [Medline].

60. Fages C, Nolo R, Huttunen HJ, Eskelinen E, Rauvala H. Regulation of cell migration by amphoterin. J Cell Sci 2000; 113: 611-620 [Abstract].

61. Parkkinen J, Raulo E, Merenmies J, Nolo R, Kajander EO, Baumann M, Rauvala H. Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem 1993; 268: 19726-19738 [Abstract/Free Full Text].

62. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-B require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274: 19919-19924 [Abstract/Free Full Text].

63. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, et al . . The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 25752-25761 [Abstract/Free Full Text].

64. Thornalley PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-Grand) 1998; 44: 1013-1023 .

65. Schmidt AM, Stern DM. RAGE: A new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab 2000; 11: 368-375 [Medline].

66. Sousa MM, Yan SD, Stern D, Saraiva MJ. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor B (NF-B) activation. Lab Invest 2000; 80: 1101-1110 [Medline].

67. Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F, Arrigoni G, Bianchi ME. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001; 152: 1197-1206 [Abstract/Free Full Text].

68. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova F, et al . . HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251 [Abstract/Free Full Text].

69. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, Tracey KJ. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999; 126: 389-392 [Medline].

70. Wankowicz Z, Megyeri P, Issekutz A. Synergy between tumour necrosis factor  and interleukin-1 in the induction of polymorphonuclear leukocyte migration during inflammation. J Leukoc Biol 1988; 43: 349-356 [Abstract].

71. Elias JA, Lentz V. IL-1 and tumor necrosis factor synergistically stimulate fibroblast IL-6 production and stabilize IL-6 messenger RNA. J Immunol 1990; 145: 161-166 [Abstract].

72. Conti P, Reale M, Fiore S, Cancelli A, Angeletti PU, Dinarello CO. Recombinant interleukin 1 and tumor necrosis factor acting in synergy to release thromboxane, 6-KETO-PGF1  and PGE2 by human neutrophils. Scand J Rheumatol Suppl 1988; 75: 318-324 [Medline].

73. Rhee P, Waxman K, Clark L, Kaupke CJ, Vaziri ND, Tominaga G, Scannell G. Tumor necrosis factor and monocytes are released during hemorrhagic shock. Resuscitation 1993; 25: 249-255 [Medline].

74. Zingarelli B, Squadrito F, Altavilla D, Calapai G, Di Rosa M, Caputi AP. Role of tumor necrosis factor- in acute hypovolemic hemorrhagic shock in rats. Am J Physiol 1994; 266: H1512-H1515 [Abstract/Free Full Text].

75. Ombrellino M, Wang H, Ajemian MS, Talhouk A, Scher LA, Friedman SG, Tracey KJ. Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock (letter). Lancet 1999; 354: 1446-1447 [Medline].

76. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000; 165: 2950-2954 [Abstract/Free Full Text].

77. Andersson U, Wang H, Palmblad K, Aveberger JC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, et al . . High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192: 565-570 [Abstract/Free Full Text].

78. Maier JA, Statuto M, Ragnotti G. Endogenous interleukin 1  must be transported to the nucleus to exert its activity in human endothelial cells. Mol Cell Biol 1994; 14: 1845-1851 [Abstract/Free Full Text].

79. Wessendorf JH, Garfinkel S, Zhan X, Brown S, Maciag T. Identification of a nuclear localization sequence within the structure of the human interleukin-1  precursor. J Biol Chem 1993; 268: 22100-22104 [Abstract/Free Full Text].

80. Grenfell S, Smithers N, Miller K, Solari R. Receptor-mediated endocytosis and nuclear transport of human interleukin 1 . Biochem J 1989; 264: 813-822 [Medline].